CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013
31 July 2024 - 4:00PM
CITRYLL COMPLETES PATIENT DOSING IN THE
REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL
ANTI-INFLAMMATORY CANDIDATE CIT-013
Oss, Netherlands – 31 July 2024 – Citryll, a
clinical-stage biotech company developing first-in-class
therapeutics to treat immune-mediated inflammatory diseases, today
announces the successful completion of dosing in the repeat dose
stage of its Phase 1 trial for its lead drug candidate CIT-013.
The Phase 1 first-in-human trial is assessing
the safety and tolerability of CIT-013. Part D of the Phase 1 trial
is investigating the safety and tolerability of repeat dosing in 9
patient volunteers with rheumatoid arthritis (RA) and 3 healthy
volunteers. All trial participants have been enrolled and
successfully completed dosing. Results are anticipated in Q4 2024,
which, if positive, would lay the groundwork for the initiation of
Phase 2a trials. Two Phase 2a studies are planned in patients with
RA and hidradenitis suppurativa (HS), Citryll’s lead indications
for CIT-013.
CIT-013 offers a novel therapeutic approach for
treating inflammatory diseases by targeting neutrophil
extracellular traps (NETs), which play a significant role in the
body’s inflammatory processes. NETs, released during NETosis, can
contribute to tissue damage and sustained inflammation when not
properly cleared by the body. CIT-013’s dual mode of actions
inhibits NET formation and promotes the clearance of existing NETs
by specifically targeting citrullinated histones, a hallmark of
NETs.
Maarten Kraan, M.D., Ph.D., CMO at
Citryll, commented: “Reaching this important milestone in
the Phase 1 study is testament to hard work across the Citryll
team. We look forward to sharing data later this year and plans for
Phase 2a trials are underway. We remain excited for the potential
of CIT-013, which has demonstrated potent anti-inflammatory effects
in preclinical models, positioning it as a potential game-changer
in rheumatoid arthritis and hidradenitis suppurativa, as well in a
wide range of inflammatory disorders.”
-ENDS-
About Citryll
Citryll has translated a deep understanding of
the neutrophil extracellular trap (NET) pathway to therapeutically
address its central role in a broad range of immune-mediated
inflammatory diseases. With a unique dual mode of action, the
company’s lead antibody, CIT-013, has reached the clinic by
demonstrating a precise and powerful ability to control NETs and
NETosis. Citryll is initially developing CIT-013 as a novel drug
for rheumatoid arthritis and hidradenitis suppurativa, which may
serve as enabling indications for a wide spectrum of autoimmune and
inflammatory diseases. The initial clinical trials with CIT-013 are
expected to provide the foundation for a new treatment paradigm for
immune-mediated inflammatory diseases.
Contacts
CitryllSjoerd van Gorp,
COOEmail: info@citryll.com
Citryll Media
ContactsICR ConsiliumAmber Fennell, Suki Virji, Lucy
FeatherstoneEmail: citryll@icrinc.com